Avista Capital gains FDA exclusivity extension for Cardiolite
Avista Capital Partners’ recently acquired medical imaging business (MI) from Bristol-Myers Squibb reported today that the FDA has granted pediatric exclusivity for studies conducted on Cardiolite (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), effective Jan. 8. This grant extends the marketing exclusivity of Cardiolite for an additional six months beyond patent expiration on Jan. 29, the company said.
D. Scott Edwards, vice president of research and development at MI, explained, “We believe that this is the first pediatric exclusivity grant for an imaging agent and is the result of extensive clinical trials, involving more than 600 patients in nine countries over three years.”
“This substantial investment by our medical imaging business reaffirms our continuing commitment to the Cardiolite brand, our customers and the improvement of patient care,” said Don Kiepert, CEO at MI.
Avista Capital Partners acquired the medical imaging business on January 8 of this year.
D. Scott Edwards, vice president of research and development at MI, explained, “We believe that this is the first pediatric exclusivity grant for an imaging agent and is the result of extensive clinical trials, involving more than 600 patients in nine countries over three years.”
“This substantial investment by our medical imaging business reaffirms our continuing commitment to the Cardiolite brand, our customers and the improvement of patient care,” said Don Kiepert, CEO at MI.
Avista Capital Partners acquired the medical imaging business on January 8 of this year.